List of Excipients in Branded Drug ENALAPRIL MALEATE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	ENALAPRIL MALEATE	enalapril maleate	50090-5292	LACTOSE
A-S Medication Solutions	ENALAPRIL MALEATE	enalapril maleate	50090-5292	MAGNESIUM STEARATE
A-S Medication Solutions	ENALAPRIL MALEATE	enalapril maleate	50090-5292	SODIUM BICARBONATE
A-S Medication Solutions	ENALAPRIL MALEATE	enalapril maleate	50090-5292	SODIUM STEARATE

Generic Drugs Containing ENALAPRIL MALEATE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	enalapril maleate	0615-4589	ANHYDROUS LACTOSE
NCS HealthCare of KY Inc dba Vangard Labs	enalapril maleate	0615-4589	HYPROMELLOSES
NCS HealthCare of KY Inc dba Vangard Labs	enalapril maleate	0615-4589	STARCH, CORN
NCS HealthCare of KY Inc dba Vangard Labs	enalapril maleate	0615-4589	STEARIC ACID

What are the Most Frequently-Used Excipients in ENALAPRIL MALEATE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
1	ANHYDROUS CITRIC ACID
41	ANHYDROUS LACTOSE
1	AQUA

Enalapril Maleate Excipient Strategy and Commercial Opportunities

Last updated: October 2, 2026

Enalapril maleate is a mature ACE inhibitor with limited value in core tablet products and stronger commercial potential in pediatric liquids, fixed-dose combinations, orally disintegrating products, and differentiated packaging. The active ingredient has no meaningful biosimilar risk, while generic competition, low pricing, and expired foundational patents constrain returns from standard tablets.

What is the regulatory and commercial status of enalapril maleate?

Enalapril maleate is the maleate salt of enalapril, a prodrug converted in vivo to enalaprilat. It is approved for hypertension and heart failure. The original branded product, Vasotec, was developed and marketed by Merck. Generic enalapril maleate tablets are widely available.

Attribute	Status
Active ingredient	Enalapril maleate
Pharmacologic class	Angiotensin-converting enzyme inhibitor
Main indications	Hypertension; symptomatic heart failure; reduction of heart-failure-related hospitalization
Common tablet strengths	2.5 mg, 5 mg, 10 mg, 20 mg
Liquid strength	1 mg/mL for commercial oral-solution products
FDA pathway for standard generics	Abbreviated New Drug Application
Biosimilar pathway	Not applicable; enalapril maleate is a small molecule
Foundational compound patents	Expired
Current market structure	Generic tablets, limited differentiated liquid products, hospital and international supply
Primary commercial constraint	Price erosion and substitution

The principal branded oral solution in the United States is Epaned, an enalapril maleate oral solution associated with Silvergate Pharmaceuticals. The product was developed for patients who cannot swallow tablets, particularly pediatric patients and patients requiring enteral administration. The FDA-approved liquid formulation is commercially more differentiated than standard tablets because it addresses taste, dose measurement, stability, and administration requirements [1].

When did enalapril maleate lose patent exclusivity?

Core enalapril maleate patent protection expired decades ago. The foundational U.S. patent commonly associated with enalapril and related N-substituted proline derivatives is U.S. Patent No. 4,374,829, issued in 1983. Its original patent term expired before the modern 20-year-from-filing framework applied to later patents [2].

Exclusivity category	Enalapril maleate position
Active pharmaceutical ingredient patent	Expired
Original branded-product exclusivity	Expired
Standard tablet formulation protection	Expired or commercially immaterial
Current pediatric-liquid differentiation	Product-specific formulation and regulatory positioning
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Generic entry risk	High for standard tablets; lower for specialized liquids

Enalapril maleate has no current composition-of-matter barrier comparable to those protecting newer cardiovascular products. New patent value must come from formulation, manufacturing, delivery, device, packaging, or a specific clinical use.

What is the Orange Book status of enalapril maleate?

FDA Orange Book listings for enalapril maleate are primarily associated with approved tablet and oral-solution products. The Orange Book is relevant for identifying listed patents, therapeutic-equivalence codes, and reference-listed drugs, but the commercial landscape is dominated by old products with limited remaining patent protection [3].

For a conventional enalapril maleate tablet, an abbreviated application generally relies on the reference product's safety and efficacy findings and demonstrates pharmaceutical equivalence and bioequivalence. A new liquid, orally disintegrating tablet, or combination product may require a more specialized regulatory strategy.

What are the likely FDA pathways for new enalapril products?

Product concept	Likely pathway	Principal regulatory issue
Conventional tablet	ANDA	Bioequivalence, inactive-ingredient suitability, manufacturing control
New oral solution equivalent to an approved product	ANDA or 505(b)(2), depending on reference and formulation	Bioequivalence, stability, preservative system, dosing device
Pediatric liquid with new concentration or flavor	505(b)(2) or ANDA, depending on product design	Dose accuracy, safety of excipients, taste acceptance
Orally disintegrating tablet	505(b)(2) or ANDA	Disintegration, bioequivalence, palatability
Enalapril/hydrochlorothiazide combination	ANDA if an appropriate reference exists	Combination-product equivalence and dosage proportionality
Enalapril plus a novel device	505(b)(2) or combination-product pathway	Device reliability and human factors

FDA guidance generally permits inactive ingredients that are already used in approved oral products, but concentration, patient population, route, and exposure remain relevant. Pediatric applications receive greater scrutiny because excipient safety margins are narrower [4].

What excipients are used in enalapril maleate tablets?

Tablet formulations vary by manufacturer. Typical excipient classes include fillers, binders, disintegrants, lubricants, glidants, and colorants. Common examples include lactose, microcrystalline cellulose, starch, pregelatinized starch, magnesium stearate, colloidal silicon dioxide, and coloring agents.

The formulation objective is not simply low-cost tablet production. Enalapril maleate is sensitive to formulation conditions that can affect chemical stability, dissolution, and content uniformity. Excipient selection should therefore address:

1. Moisture exposure.
2. Microenvironmental pH.
3. Hydrolytic degradation.
4. Blend uniformity at low dose.
5. Tablet disintegration and dissolution.
6. Packaging compatibility.

Which excipients create the greatest technical risk?

Alkaline or strongly basic excipients can create an unfavorable microenvironment for an acidic maleate salt and may affect stability or dissolution. Hygroscopic ingredients can raise water activity and increase the risk of degradation during storage. Reducing sugars may also require evaluation for compatibility with amine-containing drug substances or related impurities.

The highest-risk formulation choices are:

Excipient or condition	Potential issue
Highly alkaline excipient	Local pH shift, salt disruption, dissolution changes
Hygroscopic filler	Moisture uptake and degradation
Excessive lubricant	Slower dissolution and poor wetting
High binder level	Hard tablets and delayed disintegration
Reactive reducing sugar	Possible chemical incompatibility
Poorly controlled particle-size distribution	Blend segregation and dose variability
Inadequate container closure	Moisture-driven potency loss

A low-dose 2.5 mg tablet is particularly sensitive to blend uniformity and segregation. Direct compression can reduce exposure to water and heat, but it requires suitable powder flow and content-uniformity controls. Wet granulation may improve manufacturability but introduces water and drying variables that must be validated.

What formulation patents could protect enalapril maleate products?

The active ingredient cannot provide meaningful new patent protection by itself. Patentable subject matter is more likely to arise from a specific formulation architecture or manufacturing process.

Formulation patent opportunities

Potential claim categories include:

• A chemically defined oral-solution pH range that improves shelf life.
• A preservative system with demonstrated microbial protection and tolerability.
• A low-sugar or sugar-free pediatric liquid with improved taste.
• A taste-masked multiparticulate system.
• An orally disintegrating tablet with defined disintegration and dissolution performance.
• A moisture-resistant tablet coating and package combination.
• A stable fixed-dose combination with hydrochlorothiazide or another antihypertensive.
• A ready-to-use enteral formulation compatible with feeding tubes.
• A low-dose pediatric formulation with a calibrated dosing device.
• A process that reduces enalaprilat or other specified degradation products.

A formulation patent must claim more than a routine substitution of one conventional excipient for another. The strongest position would link a defined composition to unexpected stability, dissolution, palatability, dose accuracy, or administration performance.

What excipients are used in enalapril maleate oral solution?

The Epaned oral solution label identifies a liquid formulation containing enalapril maleate at 1 mg/mL. Listed inactive ingredients include citric acid, sodium citrate, sodium benzoate, sucralose, and flavoring components [1].

Formulation function	Example approach
pH control	Citric acid and sodium citrate buffer
Preservative	Sodium benzoate
Sweetening	Sucralose
Flavor	Fruit flavor system
Vehicle	Purified aqueous vehicle
Dose delivery	Oral syringe or calibrated measuring device

The formulation logic is commercially important. A buffered acidic environment can support chemical stability, while sodium benzoate provides microbial protection. Sucralose and flavoring address the bitter taste associated with ACE inhibitors and support pediatric use.

A liquid product must control more than assay. Development should monitor:

• Enalapril maleate assay.
• Enalaprilat formation.
• Related substances.
• pH drift.
• Preservative content and effectiveness.
• Microbial limits.
• Sedimentation or precipitation.
• Container interaction.
• Dosing-device accuracy.
• Tube compatibility.

How should a pediatric liquid be differentiated?

A commercial liquid can compete through administration performance rather than active-ingredient novelty. Relevant differentiators include:

• Lower dosing volume.
• Better taste acceptance.
• Sugar-free or alcohol-free composition.
• Compatibility with nasogastric and gastrostomy tubes.
• Unit-dose packaging.
• Child-resistant packaging.
• Longer in-use stability after opening.
• Reduced need for refrigeration.
• Clear instructions for weight-based dosing.
• A dosing syringe designed for low-volume delivery.

Pediatric excipient selection must account for exposure to preservatives, sweeteners, flavoring agents, and solvents. Products intended for infants and young children require conservative excipient choices and clear maximum daily exposure calculations.

What commercial opportunities exist for enalapril maleate?

The strongest opportunities are in products where standard generic tablets perform poorly or create practical barriers.

1. Pediatric and geriatric oral liquids

This is the clearest differentiated opportunity. Pediatric cardiology and nephrology patients may require doses below available tablet strengths. Older patients, patients with dysphagia, and patients using feeding tubes also benefit from liquids.

Commercial value comes from a combination of:

• Prescription availability.
• Dose flexibility.
• Caregiver convenience.
• Hospital formulary use.
• Reduced tablet manipulation.
• Improved adherence.

The market is narrower than the tablet market, but price competition may be less severe because fewer suppliers offer a validated liquid.

2. Fixed-dose combinations

Enalapril has a long history of use with diuretics and other cardiovascular agents. Enalapril/hydrochlorothiazide combinations can reduce pill burden and improve adherence. The opportunity is strongest in jurisdictions where the combination is approved but supply is inconsistent.

Potential barriers include:

• Existing generic competition.
• Limited reimbursement premiums.
• Combination-product bioequivalence requirements.
• Dose-ratio constraints.
• Physician preference for independent titration.

3. Orally disintegrating and dispersible tablets

An orally disintegrating tablet could target dysphagia, institutional care, and patients who cannot reliably swallow conventional tablets. A dispersible tablet could support administration through feeding tubes if it produces a reproducible dispersion without clogging.

The product must show reliable dose delivery and acceptable taste. Rapid disintegration alone is not enough to create durable differentiation.

4. Hospital and emergency-use packaging

Unit-dose blister packs, barcoded packages, and tamper-evident formats may have value in hospitals, long-term care, and automated dispensing environments. Packaging improvements are more likely to generate commercial value than a minor tablet-excipient change.

5. Emerging-market supply

Enalapril remains clinically relevant in markets where newer renin-angiotensin system products are less affordable. Opportunities include:

• Stable tablets for hot and humid climates.
• Low-cost fixed-dose combinations.
• Local blister packaging.
• Pediatric liquids.
• Supply agreements with public-health systems.
• Contract manufacturing for regional distributors.

Geographic differentiation depends on local registration, manufacturing economics, reference-product availability, and tender pricing. The United States is likely to remain a low-margin tablet market, while selected emerging markets may support volume-based opportunities.

How strong is the patent estate for enalapril maleate?

The core patent estate is weak because the foundational patents have expired and conventional tablets are widely available. A new entrant would face limited patent barriers but substantial price competition.

Estate component	Strength
Composition of matter	Very weak; expired
Standard tablet formulation	Weak
Oral-solution formulation	Moderate if claims are narrow and technically supported
Pediatric delivery system	Moderate
Taste masking	Moderate but vulnerable to design-around
Fixed-dose combination	Weak to moderate, depending on formulation claims
Manufacturing process	Moderate if process-specific and difficult to reproduce
Packaging and device	Moderate, usually narrow
Method-of-use patents	Limited commercial value for established indications

A formulation patent may protect a product from direct copying, but it is unlikely to prevent all generic entry. Competitors can often design around buffer concentration, preservative selection, flavor system, particle architecture, or packaging.

Which companies are challenging or competing with enalapril products?

Competition is fragmented among generic manufacturers and branded or specialty-product suppliers. Standard tablet suppliers may include large generic companies and regional manufacturers. Specialty competition is more relevant for oral solutions and pediatric products.

The principal competitive groups are:

• Generic tablet manufacturers.
• Specialty pediatric pharmaceutical companies.
• Contract manufacturers with liquid-filling capability.
• Hospital-supply manufacturers.
• Fixed-dose combination suppliers.
• Regional distributors in emerging markets.

Public information generally does not support a single global competitor ranking for enalapril maleate because product availability varies by country and many companies do not report product-level revenue.

What generic launch scenarios exist?

Conventional tablet launch

This is the fastest and least differentiated route. It requires efficient manufacturing, reliable active-ingredient supply, and aggressive pricing. The principal risk is rapid price erosion.

Pediatric-liquid launch

This route requires more development work but can produce a stronger commercial position. The key risks are stability, preservative effectiveness, flavor acceptance, dosing-device performance, and pediatric regulatory review.

Fixed-dose combination launch

This route can capture adherence-driven demand but faces established generic competition and limited pricing power.

Advanced formulation launch

An orally disintegrating, dispersible, or enteral-compatible product can obtain differentiation through usability. Patent protection is possible but usually narrow.

What litigation and settlement risks affect enalapril maleate?

There is no current high-profile patent litigation comparable to disputes involving recently launched specialty medicines. Foundational enalapril litigation is historical rather than a current market-entry barrier.

For a new product, legal risk is more likely to involve:

• Orange Book patent certification.
• ANDA paragraph IV challenges against any listed formulation patents.
• Trade dress or trademark disputes involving branded liquid products.
• Manufacturing-process patents.
• Labeling and method-of-use claims.
• Product liability associated with dosing errors or pediatric administration.

A paragraph IV challenge would be commercially relevant only if a current listed patent covered a differentiated liquid, device, or combination product. For a standard enalapril maleate tablet, the primary barriers are regulatory execution and economics rather than patent litigation.

What licensing deals could create value?

Licensing opportunities are more likely to involve product platforms than the enalapril molecule. Relevant assets include:

• Pediatric liquid technology.
• Taste-masking systems.
• Stabilized aqueous formulations.
• Unit-dose packaging.
• Oral syringe and dosing-device technology.
• Regional registration and distribution rights.
• Fixed-dose combination dossiers.
• Contract manufacturing capacity.

A license covering only enalapril maleate would have limited strategic value. A broader cardiovascular formulation platform could support a more attractive transaction by bundling enalapril with lisinopril, captopril, losartan, hydrochlorothiazide, or amlodipine products.

What is the investment case for enalapril maleate excipient innovation?

The investment case is defensive and operational rather than discovery-driven. A successful product should solve a specific administration or stability problem and reach a market with limited direct competition.

The most attractive profile is:

1. A stable 1 mg/mL or comparable pediatric liquid.
2. A differentiated flavor and preservative system.
3. A validated dosing device.
4. Tube compatibility.
5. Broad geographic registration.
6. A formulation patent supported by comparative stability or palatability data.
7. Contract-manufacturing scalability.
8. A portfolio strategy covering multiple cardiovascular drugs.

Standard tablets can provide volume but generally do not justify substantial formulation investment unless manufacturing cost is materially lower or a regional supply gap exists.

Key Takeaways

• Enalapril maleate's foundational patent protection has expired.
• Standard tablets are highly commoditized and exposed to price erosion.
• Pediatric and dysphagia-friendly oral liquids offer the clearest commercial differentiation.
• Citric acid, sodium citrate, sodium benzoate, sucralose, and flavoring are representative excipient strategies for an aqueous product.
• Moisture control, microenvironmental pH, hydrolysis, taste, and dosing accuracy are the main formulation issues.
• New patent value is most likely in formulation, device, packaging, manufacturing, or administration claims.
• Biosimilar risk is irrelevant because enalapril maleate is a small molecule.
• Fixed-dose combinations and orally disintegrating products offer secondary opportunities.
• Licensing should focus on delivery and formulation technologies rather than the active ingredient.
• The best commercial strategy is a differentiated liquid or administration system supported by reliable manufacturing and targeted geographic distribution.

FAQs

Is enalapril maleate still commercially attractive?

Yes, but mainly in differentiated formats. Standard tablets are low-margin generic products, while pediatric liquids, fixed-dose combinations, and specialized delivery formats can support better economics.

Can a new enalapril maleate oral solution receive patent protection?

Yes. Protection may be available for a defined buffer system, preservative combination, taste-masking architecture, stability profile, dosing device, or manufacturing process. The claims must provide a non-obvious technical result.

Which excipient is most important for enalapril maleate liquid stability?

The buffer system is central because pH affects degradation and product shelf life. Preservative compatibility, container closure, and microbial protection are also critical.

Does enalapril maleate require a biosimilar development program?

No. Enalapril maleate is a chemically synthesized small molecule. Generic development generally proceeds through an ANDA or, for certain differentiated products, a 505(b)(2) application.

What is the strongest geographic opportunity for a new enalapril formulation?

The strongest opportunity is usually a market with pediatric liquid demand, limited specialty competition, and weak local supply. Emerging markets can support volume, while the United States offers a more established regulatory framework but greater generic price pressure.

References

1. U.S. Food and Drug Administration. (n.d.). Epaned: Enalapril maleate oral solution prescribing information.
2. United States Patent and Trademark Office. (1983). U.S. Patent No. 4,374,829: N-substituted proline derivatives.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2009). Guidance for industry: Pediatric information incorporated into human prescription drug and biological product labeling.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.